Literature DB >> 32818278

Reading Speed as an Objective Measure of Improvement Following Vitrectomy for Symptomatic Vitreous Opacities.

Edwin H Ryan, Linda A Lam, Christine M Pulido, Steven R Bennett, Aurélie Calabrèse.   

Abstract

BACKGROUND AND
OBJECTIVE: There is currently no objective measure of the visual deficits experienced by patients with symptomatic vitreous opacities (SVOs) that would also correlate with the functional improvement they report following vitrectomy. This study aims to determine whether reading speed can be used as a reliable outcome measure to assess objectively the impact of both SVOs and vitrectomy on patients' visual performance. PATIENTS AND METHODS: Twenty adult patients seeking surgery for SVO were included. Measures of visual function were obtained before and after vitrectomy using the Early Treatment Diabetic Retinopathy Study acuity chart, the National Eye Institute Visual Function Questionnaire, and the MNREAD acuity chart.
RESULTS: In patients with nonopacified lenses (n = 10), maximum reading speed increased significantly from 138 to 159 words per minute after complete removal of SVOs by vitrectomy (95% confidence interval, 14-29; P < .001).
CONCLUSIONS: Reading speed is impaired with SVOs and improves following vitrectomy in phakic and pseudophakic eyes with clear lenses. Reading speed is a valid objective measure to assess the positive effect of vitrectomy for SVOs on near-distance daily life activities. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:456-466.]. Copyright 2020, SLACK Incorporated.

Entities:  

Mesh:

Year:  2020        PMID: 32818278     DOI: 10.3928/23258160-20200804-06

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  1 in total

1.  Visualization and Grading of Vitreous Floaters Using Dynamic Ultra-Widefield Infrared Confocal Scanning Laser Ophthalmoscopy: A Pilot Study.

Authors:  Gerardo Garcia-Aguirre; Andree Henaine-Berra; Guillermo Salcedo-Villanueva
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.